Evidence map›Paper›PMID 23617340›Full record

ArticleExpert review of anticancer therapy2013

Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?

Peter Storz

Open access · bronzeAbstract readEditorial
In one paragraph

Article in Expert review of anticancer therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Design and Synthesis of Novel Aminoindazole-pyrrolo[2,3-Molecules (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Expression of NF-κB-inducing kinase in breast carcinoma tissue and its clinical significance.International journal of clinical and experimental pathology · 2015
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Peter Storz
Mayo Clinic in Florida · US

Funding

Protein Kinase D in oncogenic oxidative stress signalingR01CA140182 · NCI · MAYO CLINIC JACKSONVILLE · PI STORZ, PETER · 2010 to 2014
$1.5M
Role of Protein Kinase D in Pancreatic CancerR21CA135102 · NCI · MAYO CLINIC JACKSONVILLE · PI STORZ, PETER · 2008 to 2009
$379k
NCI NIH HHS R01 CA140182NCI NIH HHS R01-CA140182NCI NIH HHS R21 CA135102NCI NIH HHS R21-CA135102
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic AgentsDelayed DiagnosisDrug DesignHumansMolecular Targeted TherapyNF-kappa BPancreatic NeoplasmsSignal TransductionAntineoplastic AgentsNF-kappa B

Identifiers

PMID23617340
PMCPMC3800143
OpenAlexW2152569303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.